Status
Conditions
Treatments
About
This study is designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter in the Chinese population.
Full description
This is a prospective, multi-center, open-label, randomized, controlled, non-inferiority clinical trial designed to evaluate the effectiveness and the safety of the PowerMeTM Midline Catheter compared to PIVC in the Chinese population in order to support the product's registration in China.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Coagulation disorder or active bleeding;
Skin injury, infection, or dermatosis at the site to be punctured;
History of radiotherapy, thrombosis, or vascular surgery; arteriovenous fistula or phlebitis history at the area and/or vein to be catheterized;
History of mental illness;
End stage renal disease requires vein protection;
Conditions with decreased venous flow in the extremity, such as lymphedema of the arm, etc.;
Infusions of vesicant or irritant drugs, hyperosmotic infusate (the osmotic pressure >900mOsm/L in this study), parenteral nutrition, etc., which are not suitable for peripheral intravenous infusion (If other appropriate venous access is established for the aforementioned infusates, the patient may be enrolled).
The evaluation of the upper limb veins is Grade II, the evaluation grade is as following:
Self-reported being pregnant or lactating;
Other conditions that the investigator considers improper for the study;
Participating in another study or already enrolled.
Primary purpose
Allocation
Interventional model
Masking
256 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal